Comparison of stepwise addition of prandial insulin to a basal-bolus regimen when basal insulin is insufficient for glycaemic control in type 2 diabetes: Results of the OSIRIS study

Diabetes and Metabolism

Volumn 38, Issue 6, 2012, Pages 507-514

  Raccah, D ^a   Haak, T J ^b   Huet, D ^c   Monnier, L ^d   Robertson, D ^e   Labard, P ^f   Soler, J ^g   Penfornis, A ^h  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b Diabetes Zentrum   (Germany)

^c Centre Hospitalier Saint Joseph   (France)

^d LAPEYRONIE HOSPITAL   (France)

^e SANDWELL GENERAL HOSPITAL   (United Kingdom)

^f SANOFI   (France)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h Bâtiment Socrate   (France)

Author keywords

Basal bolus; Insulin glargine; Insulin glulisine; Prandial insulin; Randomised trial; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN SECRETAGOGUE; METFORMIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRONCHITIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEIZURE; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; MALE; MIDDLE AGED;

EID: 84870700871     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2012.08.010     Document Type: Article

References (21)

1. Hamaty M. Insulin treatment for type 2 diabetes: when to start, which to use. Cleve Clin J Med 2011, 78:332-342.
2. DeWitt D.E., Hirsch I.B. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003, 289:2254-2264.
3. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American diabetes association (ADA) and the european association for the study of diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
4. Wright A., Burden A.C., Paisey R.B., Cull C.A., Holman R.R. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective diabetes study (UKPDS 57). Diabetes Care 2002, 25:330-336.
5. Raccah D., Bretzel R.G., Owens D., Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough - what next?. Diabetes Metab Res Rev 2007, 23:257-264.
6. Nyenwe E.A., Jerkins T.W., Umpierrez G.E., Kitabchi A.E. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 2011, 60:1-23.
7. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26:881-885.
8. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002, 26(Suppl. 3):S18-S24.
9. Grant R., Adams A.S., Trinacty C.M., Zhang F., Kleinman K., Soumerai S.B., et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care 2007, 30:807-812.
10. Reach G. Patient non-adherence and healthcare-provider inertia are clinical myopia. Diabetes Metab 2008, 34(4 Pt. 1):382-385.
11. Del Prato S., Nicolucci N., Lovagnini-Scher A.C., Turco S., Leotta S., Vespasiani G. Telecare provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine. The ELEONOR study. Diabetes Technol Ther 2012, 14:175-182.
12. Lankisch M.R., Ferlinz K.C., Leahy J.L., Scherbaum W.A. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008, 10:1178-1185.
13. Nicolucci A., Del Prato S., Vespasiani G. Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction. Diabetes Care 2011, 34:2524-2526.
14. Hermansen K., Kumar S., Mersebach H., Svendsen A.L., Meneghini L. The STEPwise™ randomised, controlled, 48-week trial: intensifying treatment with stepwise addition of prandial insulin aspart, based on largest prandial glucose increment or largest meal, to once-daily basal insulin detemir in subjvsects with type 2 diabetes. Diabetologia 2010, 53(Suppl. 1):S381-S382.
15. Delamater A.M., Jacobson A.M., Anderson B., Cox D., Fisher L., Lustman P., et al. Psychosocial therapies in diabetes: report of the psychosocial therapies working group. Diabetes Care 2001, 24:1286-1292.
16. Ilag L.L., Kerr L., Malone J.K., Tan M.H. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther 2007, 29(6 Pt. 1):1254-1270.
17. Garber A.J. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006, 66:31-49.
18. Perfetti R. Combining basal insulin analogs with glucagon-like peptide-1 mimetics. Diabetes Technol Ther 2011, 13:873-881.
19. Del Prato S., Tiengo A. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes Metab Res Rev 2001, 17:164-174.
20. Holman R.R., Thorne K.I., Farmer A.J., Davies M.J., Keenan J.F., Paul S., et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007, 357:1716-1730.
21. Monnier L., Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes Metab 2006, 32:7-13.